Secura Bio
NV - Las VegasBiotechnology
Focus: Secura Bio is a Las Vegas-based oncology-focused biotech company founded in 2019 that specializes in acquiring and commercializing therapies worldwide. The company is publicly traded and generates 100% of its revenue from COPIKTRA (duvelisib), a PI3K inhibitor for hematologic malignancies.
Profile data last refreshed 7h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
5-1 this month
Stable — net -1 jobs in 30d
2 added, 3 removed. Backfill posture.
Should You Work at Secura Bio?
AI assessmentSecura Bio offers commercial stability through a marketed oncology asset but represents a high-risk, capital-light acquisition-and-licensing model with limited growth opportunities for most career paths.
Why Work Here
- Established commercial product with $21M in Part D spending and patent protection extending to 2035 provides revenue stability and recurring commercial roles.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
10 total
LOE Risk
1 imminent
FARYDAK
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$21M (Part D)Stable
Peak
Help build intelligence for Secura Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.